Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).

J Bone Oncol · 2018 · PMC6303395 · PMID 30591866

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

of borderline significanceP = 0.07so close (0.05 < p ≤ 0.1)

The test for interaction (TFI) by menopause on DFS was of borderline significance (Chi 2 = 3.25, P = 0.07).

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.